Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2023-01-02 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物监事会关于公司2022年限制性股票激励计划首次授予激励对象名单的审核意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board of a company regarding the review and public disclosure of the initial list of recipients for a 2022 restricted stock incentive plan. It includes details about the internal and external compliance checks, legal qualifications of the incentive recipients, and confirmation that no objections were raised during the public notice period. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation of financial results. Instead, it is an official announcement related to the company's stock incentive plan and compliance with regulatory requirements. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Capital/Financing Update.
2023-01-02 Chinese
益方生物科技（上海）股份有限公司2022年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as the "2022 Restricted Stock Incentive Plan Implementation Assessment Management Measures" of a company. It details the rules, principles, scope, assessment institutions, performance assessment indicators, procedures, and management of assessment results related to the implementation of a restricted stock incentive plan. It is a governance-related document focusing on the company's internal incentive and performance evaluation mechanisms for stock incentives. It does not contain financial statements, audit information, earnings data, or regulatory filings. It is not a report of voting results or a proxy solicitation. It is not a presentation or announcement of financing or capital changes. The document is about governance and management of stock incentive plans, which falls under governance information rather than other categories. Therefore, the most appropriate classification is Governance Information (CGR). The document length is over 5,000 characters and contains substantive content, so it is not a mere announcement or regulatory filing.
2022-12-23 Chinese
君合律师事务所上海分所关于益方生物2022年限制性股票激励计划（草案）的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a 2022 restricted stock incentive plan (股权激励计划) for a listed company, 益方生物科技（上海）股份有限公司. It discusses the legal compliance, procedures, eligibility, and details of the stock incentive plan, including the number of shares, allocation, vesting, and restrictions. The document references Chinese securities laws, stock exchange rules, and regulatory approvals. It is not a financial report, earnings release, or a simple announcement but a comprehensive legal opinion related to a capital incentive plan. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock incentives. The document length is substantial (over 12,000 characters), and it contains substantive content rather than just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2022-12-23 Chinese
监事会关于公司2022年限制性股票激励计划（草案）的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion on the company's 2022 restricted stock incentive plan draft. It discusses compliance with relevant laws and regulations, qualifications of incentive recipients, and the plan's alignment with corporate governance. It does not contain financial statements or detailed financial data, nor is it an announcement of voting results or a proxy solicitation. It is a regulatory compliance and governance-related opinion document. Given its nature and length (1554 characters), it is not a full report but a regulatory filing related to governance and compliance. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-12-23 Chinese
益方生物2022年限制性股票激励计划首次授予激励对象名单
Share Issue/Capital Change Classification · 95% confidence The document is titled as a list of recipients for a 2022 restricted stock incentive plan (限制性股票激励计划首次授予激励对象名单) for a company. It details the allocation of restricted stock to employees and reserved shares, with percentages and notes on the plan's terms. This is a disclosure related to stock incentives granted to employees, which is a form of share-based compensation announcement. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory certification or voting result. The document is short (908 characters) and focused on the initial grant of restricted stock under an incentive plan. This fits best under the category of Share Issue/Capital Change (SHA), as it announces the issuance of restricted shares as part of a stock incentive plan.
2022-12-23 Chinese
益方生物关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2023 first extraordinary general meeting of shareholders (临时股东大会) for a company, including information on meeting date, voting methods, agenda items, and proxy forms. It does not contain financial statements or results but is an announcement related to a shareholder meeting. The document length is 3835 characters, which is relatively short and consistent with a meeting notice rather than a full report. It includes agenda items for shareholder voting but no voting results or financial data. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2022-12-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.